Original news and analysis on international IP policy
The country that made smoking cool is now taking steps to make it uncool. France this week organised what it defined as "the first international ministerial meeting" on plain packaging for tobacco products, gathering countries that support the public health measure aimed at discouraging tobacco use.
A recent paper by public health experts argues that a treaty on ‘medicines crime’ to combat counterfeit and substandard medicines may not be the best step forward. Rather, it proposes to form an international agreement to “ensure that all proven effective and necessary medicines are affordable, available, and of assured quality,” if the goal is to protect the interests of people and public health.
A new developing country policy brief warns against use of the investor-state dispute settlement mechanism, arguing that it has a low capacity to adapt to exceptional circumstances that can afflict developing countries.
European Trade Commissioner Cecilia Malmström said in a recent speech that providing she has the backing of the College of Commissioners, the Council and the European Parliament, she would like to answer positively to the request by least developed countries (LDCs) to extend a particular exemption to enforce intellectual property rights on medical products as long as they remain an LDC.
An agreement entered into by a range of international organisations and others announced this week is expected to lower the price of early infant HIV diagnostic technologies by 35 percent, according to the parties.
Third World Network reports: New Delhi, 20 July (K M Gopakumar) – Member States of the World Health Organization have decided to continue the negotiations on a Framework of Engagement with Non-State Actors (FENSA) as several key issues remain unresolved.
Despite progress in recent years to boost local pharmaceutical production in developing countries, policy coherence across the countries is lacking, according to an official at the United Nations Conference on Trade and Development (UNCTAD).
In 1976, Yambuku village school headmaster Mabalo Lokela felt sick when he returned from a trip to northern Zaire near the Central African Republic border. He had a high fever, diarrhea, and bleeding. Because he was initially believed to have malaria, Lokela was given quinine, but his symptoms got worse and he soon died. Shortly afterwards, those who had been in contact with Lokela also died. ... Almost four decades later, there is still no cure for Ebola, despite the fact that drug development on average takes about a third of this time frame, write William Fisher and Quentin Palfrey.
A new paper released earlier this month finds that the commons perspective, which embraces knowledge as a shared resource and its management a joint responsibility, could contribute to EU policy discussions and yield better policy outcomes in areas such as health, environment, science and culture, and the internet.
The Trans-Pacific Partnership (TPP), part of US President Barack Obama’s promised pivot to Asia, has stirred up a hornet’s nest on the ethics of trying to hammer out a trade deal in secrecy. But it is not the only one. A proposed trade agreement in Asia, the Regional Comprehensive Economic Partnership (RCEP), is facing the same hiccups and flak.
World Trade Organization members this week could not decide on a request from least-developed countries to extend a waiver allowing them to forego the enforcement of intellectual property rights on pharmaceutical products until their economies are stronger. Discussions are expected to be conducted informally until the next meeting of the organisation’s council on IP rights in October.
From the New York Times: WASHINGTON — Facing resistance from its Pacific trading partners, the Obama administration is no longer demanding protection for pharmaceutical prices under the 12-nation Trans-Pacific Partnership, according to a newly leaked “transparency” annex of the proposed trade accord.
But American negotiators are still pressing participating governments to open up the process that sets reimbursement rates for drugs and medical devices. Public health professionals, generic drugmakers and activists opposed to the trade deal, which is still being negotiated, contend that it will empower big pharmaceutical firms to command higher reimbursement rates in the United States and abroad, at the expense of consumers.